CHS Survey on Gene Therapy Results
This past summer, the Canadian Hemophilia Society (CHS) conducted an on-line survey on attitudes to and knowledge about gene therapy. The results were presented and discussed at the CHS Blood Safety and Supply Committee special meeting on gene therapy this autumn in Toronto.
The survey, whose answers were anonymous, was targeted at Canadian residents with severe hemophilia A or B, fourteen years of age or older, who represent the patient group that might consider taking gene therapy in the next five years.
Go to CHS CONTACT to read more about the results of the survey.
|